Adalimumab
Major cardiac events not more common in patients receiving JAK inhibitors vs adalimumab
The risks for major adverse cardiac events and venous thromboembolism in patients with rheumatoid arthritis did not significantly differ between those receiving Janus kinase inhibitors or adalimumab, according to data.
Humira biosimilars Hyrimoz, Hulio show ‘positive clinical outcomes’ for patients with IBD
Two adalimumab biosimilars, adalimumab-adaz and adalimumab-fkjp, demonstrated safety and effectiveness in patients with Crohn’s disease and ulcerative colitis, according to a study in PLOS One.
Humira biosimilar approval paused after FDA finds ‘deficiencies’ at manufacturing facility
The FDA approval of Alvotech’s Humira biosimilar is on hold until the company can address “certain deficiencies” the administration found during an inspection of a manufacturing facility, according to a press release.
Olokizumab bests placebo, noninferior to adalimumab in RA with methotrexate
Olokizumab demonstrated superiority compared with placebo and non-inferiority compared with adalimumab in patients with rheumatoid arthritis who were receiving methotrexate as a maintenance therapy, according to data.
Adalimumab biosimilar, originator comparable in efficacy, safety in psoriasis treatment
A novel biosimilar for adalimumab was associated with bio-equivalent pharmacokinetics and safety as the reference product in patients with moderate to severe plaque psoriasis, according to study findings.
Biosimilars to shake up US drug market in 2023 and beyond despite ‘problem of complexity’
ORLANDO — Despite the glacial pace of biosimilar uptake in the United States so far, their use is expected to cut drug costs by $54 billion over the next decade, noted a presenter at the 2022 Rheumatology Nurses Society Conference.
‘One of the few strategy trials in PsA’: CONTROL sheds light on escalation, biologic use
Although there are plenty of drugs to treat psoriatic arthritis, and plenty of studies about those drugs individually, there are fewer trials examining strategies to treat patients who fail to respond to methotrexate in the first line.
VIDEO: Symptom management is ‘critical’ for treatment continuation in prostate cancer
Healio spoke with Daniel P. Petrylak, MD, about a presentation the American Urological Association meeting that focused on discontinuation rates of hormone therapy options among patients with advanced prostate cancer.
VIDEO: Treating prostate cancer in older men with next generation therapy plus upfront ADT
In this video, Daniel P. Petrylak, MD, discussed a presentation investigating androgen deprivation therapy plus upfront docetaxel in the treatment of patients 75 years or older with prostate cancer.
Top in GI: Updates on acute hepatitis outbreak; Crohn’s disease remission
During the International Liver Congress, experts provided updates on the growing outbreak of acute, severe hepatitis of unknown etiology in children.